Effect of secukinumab in combination with methotrexate in the treatment of moderate-to-severe psoriasis
Objective To investigate the clinical effects and adverse reactions of secukinumab in combination with methotrexate(MTX)in moderate-to-severe psoriasis.Methods A total of 97 patients with moderate-to-severe psoriasis from the department of Dermatology and Medical Cosmetology at 903 Hospital between June 2021 and September 2023 were enrolled in this study.The patients were randomly divided into the observation group(n=48)and the control group(n=49),in accordance with the random number table.The control group received treatment with MTX,while the observation group received treatment with secukinumab in combination with MTX.Patients in both groups underwent a 12-week treatment period.The clinical parameters of patients in both groups were further compared,including the total effective rates,the levels of inflammatory factors(TNF-α,IL-17 and IL-23),psoriasis area severity index(PASI),the body surface area(BSA)and the incidence of adverse reactions.Results There was no statistical difference in the total effective rates between the two groups(P＞0.05),with 97.92％(47/48)for the observation group and 91.84％(45/49)for the control group.After the treatment,the levels of TNF-α,IL-17 and IL-23 were reduced compared with those before the treatment(all P＜0.05),and the more reductions were observed in the observation group compared with the control group(all P＜0.05).After the treatment,the PASI and BAS scores were decreased compared with those before the treatment(all P＜0.05),and the more reductions were observed in the the observation group compared with the control group(all P＜0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P＞0.05),with 10.42％(5/48)for the observation group and 8.16％(4/49)for the control group.Conclusion The combination of secukinumab and MTT demonstrates remarkable efficacy for patients with moderate-to-severe psoriasis,effectively decreasing psoriasis area,severity,and incidence of adverse reactions.
PsoriasisSecukinumabMethotrexateDegree of skin lesionsAdverse reactions
NETL
NSTL
万方数据
